News >

Combos Could Unlock Major Immunotherapy Benefits in Ovarian Cancer

Kristi Rosa
Published: Thursday, Nov 21, 2019

John Hays, MD, PhD, an assistant professor in the Department of Internal Medicine, and member of the Translational Therapeutics Program at the Ohio State University Comprehensive Cancer Center-James

John Hays, MD, PhD

The role of immunotherapy continues to evolve in ovarian cancer, and to improve on the modest activity seen with single agents, researchers are exploring this class of drugs in combination with chemotherapy and targeted therapies, said John Hays, MD, PhD.
... to read the full story
To Read the Full Story

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Publication Bottom Border
Border Publication